Atossa Therapeutics Investor Relations Material
Latest events
Status Update
Atossa Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Atossa Therapeutics Inc
Access all reports
Atossa Therapeutics Inc. is a clinical-stage biopharmaceutical company developing medicines that address significant unmet medical needs in oncology, with a specific focus on breast cancer. The company's lead program is Endoxifen, an active metabolite of tamoxifen, currently in clinical trials for the treatment and prevention of breast cancer. Additionally, Atossa is working on AT-H201 for lung injury caused by cancer treatment and is involved in developing immunotherapy/chimeric antigen receptor therapy programs. The company is headquartered in Seattle, Washington, and its shares are listed on the NASDAQ.
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
ATOS
Country
🇺🇸 United States